RE:RE:RE:RE:Angiogenesis Foundation Study Published:Tencents wrote: It could be interesting of course - it would probably take 20 years to get to a marketable product
the apparent benefits of the compounds were first studied in 1940 - so it's not moving at a tremendous pace
Oats have been used for centuries on the skin. Aveeno and Neutragena are major brands and use CZO's active ingredients for a number of skin applications. Gold Bond is used for eczema. CZO now has data to support potential scientific claims for avenanthramide and beta glucan. Juvente has said it uses the highest concentration of beta glucan on the market. It uses both active ingredients in the same product unlike Aveeno and Neutragena. PGX is expected to reach limited commercial scale production this year as well as the decision point for mass industrialization. CZO could produce PGX-oat beta glucan/Avenanthramide for a Super Aveeno. Beta glucan is also a delivery vehicle to the deepest level of the skin.
CZO has already developed a beta glucan pill and avenanthramide pill. The beta glucan pill has been tested in a human trial and the avenanthramide pill is currently in clinical trials. Insights with the Angiogenesis Foundation study could support new studies. The avenanthramide pill is up for potential partnership with the completion of the Phase I/IIa study. The results could support a deal.
While pharma claims can take a long time wound healing studies can be relatively short.